What's Happening?
A recent Phase I/II clinical trial led by researchers at Washington University School of Medicine in St. Louis has demonstrated promising results in treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) using a CRISPR-modified stem
cell transplant. The study involved 30 adult patients at high risk of relapse, who received a stem cell transplant with CD33 removed from donor cells using CRISPR technology. This approach aims to prevent cancer recurrence by avoiding the toxicity associated with targeting CD33, a protein present on both cancerous and healthy myeloid cells. The trial also included a maintenance therapy with gemtuzumab ozogamicin, an FDA-approved drug for CD33-positive AML, which helps prevent relapse but carries risks of liver toxicity and blood cell damage.
Why It's Important?
This development is significant as it offers a potential new treatment pathway for patients with aggressive blood cancers like AML and MDS, which are challenging to treat with existing therapies such as CAR T cells. The use of CRISPR technology to modify stem cells could reduce the risk of relapse and improve patient outcomes by minimizing the destruction of healthy cells. The study's findings could pave the way for combining CD33-deleted stem cell transplants with targeted immunotherapies, potentially enhancing the effectiveness of cancer treatments and offering hope to patients with limited options.
What's Next?
The study lays the groundwork for future research into combining CD33-deleted stem cell transplants with CD33-targeted immunotherapies, such as CAR T cells. Researchers are hopeful that these combined approaches will improve treatment outcomes for patients with aggressive blood cancers. Further clinical trials will be necessary to validate these findings and explore the long-term benefits and safety of this innovative treatment strategy.
